Loading...
XHKG
6628
Market cap82mUSD
Jun 06, Last price  
1.49HKD
1D
-1.32%
1Q
-16.76%
IPO
-90.69%
Name

Transcenta Holding Limited

Chart & Performance

D1W1MN
P/E
P/S
52.48
EPS
Div Yield, %
Shrs. gr., 5y
-1.89%
Rev. gr., 5y
-23.91%
Revenues
11m
-79.09%
44,140,00080,980,00050,242,000101,892,00053,849,00011,261,000
Net income
-290m
L-37.24%
-437,354,000-322,900,000-1,715,543,000-406,745,000-462,570,000-290,292,000
CFO
0k
P
-234,960,000-174,398,000-384,499,000-295,807,000-358,043,0000

Profile

Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs in the People's Republic of China and the United States. The company develops MSB2311, a humanized PD-L1 monoclonal antibody (mAb) candidate for TMB-H solid tumors; TST001, a humanized claudin 18.2 mAb candidate for solid tumors, such as gastric cancer and is under Phase II clinical trial; TST005, a PD-L1/TGF-ß bi-functional antibody candidate which is under Phase Ia clinical trial for solid tumors, including certain lung cancers; TST010, an antibody candidate targeting regulatory T cells to enhance T cell mediated tumor killing;TST002 (Blosozumab), a humanized sclerostin mAb candidate for osteoporosis; and TST004, a humanized mannan-binding lectin serine protease 2 (MASP 2) mAb candidate for IgA kidney diseases. It also develops TST003, an antibody candidate targeting a novel immune regulatory protein produced by tumor-associated fibroblasts or tumor cells with mesenchymal phenotype; TST006, a bi-specific claudin 18.2/PD-L1 antibody; TST008, a tri-functional antibody combining a MASP2 antibody fused with a truncated transmembrane activator and CAML interactor protein; MSB0254, a humanized VEGFR-2 mAb candidate for solid tumors and is under Phase Ib/IIa clinical trials; and MSB2311, A humanized PD-L1 mAb Candidate for solid tumors and is under Phase Ib/IIa clinical trials Transcenta Holding Limited has collaboration agreements with Eli Lilly and Company, Alebund Pharmaceuticals, and Merck. The company was formerly known as MabSpace International Limited and changed its name to Transcenta Holding Limited in June 2019. Transcenta Holding Limited was incorporated in 2010 and is headquartered in Suzhou, the People's Republic of China.
IPO date
Sep 29, 2021
Employees
318
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
11,261
-79.09%
53,849
-47.15%
101,892
102.80%
Cost of revenue
199,313
471,366
480,847
Unusual Expense (Income)
NOPBT
(188,052)
(417,517)
(378,955)
NOPBT Margin
Operating Taxes
250
(250)
(246)
Tax Rate
NOPAT
(188,302)
(417,267)
(378,709)
Net income
(290,292)
-37.24%
(462,570)
13.72%
(406,745)
-76.29%
Dividends
Dividend yield
Proceeds from repurchase of equity
(9,113)
(2,037)
BB yield
0.62%
0.15%
Debt
Debt current
219,631
381,661
392,843
Long-term debt
48,443
50,173
26,477
Deferred revenue
58,300
66,300
Other long-term liabilities
75,158
Net debt
97,358
(115,454)
(527,349)
Cash flow
Cash from operating activities
(358,043)
(295,807)
CAPEX
(15,760)
(22,224)
Cash from investing activities
57,470
(102,607)
Cash from financing activities
(47,202)
26,723
FCF
(99,074)
(392,376)
(328,235)
Balance
Cash
169,423
546,026
895,450
Long term investments
1,293
1,262
51,219
Excess cash
170,153
544,596
941,574
Stockholders' equity
754,007
(3,629,978)
(3,046,277)
Invested Capital
907,248
5,125,538
4,996,699
ROIC
ROCE
EV
Common stock shares outstanding
404,791
407,032
432,827
Price
0.63
-82.45%
3.59
15.81%
3.10
-67.02%
Market cap
255,018
-82.55%
1,461,246
8.90%
1,341,764
-22.25%
EV
352,376
1,345,792
960,212
EBITDA
(188,052)
(363,726)
(323,688)
EV/EBITDA
Interest
16,017
17,636
Interest/NOPBT